NCT02830438 is a NA clinical trial of Shear wave elastography in Acute Kidney Disease, sponsored by Albert Einstein Healthcare Network.

Who is sponsoring NCT02830438?

NCT02830438 is sponsored by Albert Einstein Healthcare Network.

What drugs are being tested in NCT02830438?

Interventions in NCT02830438: Shear wave elastography.

What condition does NCT02830438 study?

NCT02830438 studies Acute Kidney Disease, Chronic Kidney Disease.

Is NCT02830438 still recruiting?

NCT02830438 is currently terminated. Last updated 5 June 2020.

Are results published for NCT02830438?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2020-06-05 · How we verify

NCT02830438

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Shear Wave Elastography in Native Kidney Disease

Terminated NA Results posted Last updated 5 June 2020

What this trial tests

NA trial testing Shear wave elastography in Acute Kidney Disease in 8 participants. Terminated before completion.

Timeline

1 July 2016

Primary endpoint
10 June 2018

10 June 2018

Quick facts

Lead sponsor	Albert Einstein Healthcare Network
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	8
Start date	1 July 2016
Primary completion	10 June 2018
Estimated completion	10 June 2018
Sites	1 location across United States

Drugs / interventions tested

Shear wave elastography

Conditions studied

Acute Kidney Disease — all drugs for Acute Kidney Disease →
Chronic Kidney Disease — all drugs for Chronic Kidney Disease →

Sponsor

Albert Einstein Healthcare Network

Who can join

18 and older, any sex, with Acute Kidney Disease or Chronic Kidney Disease. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Shear Wave Velocity of Kidney Parenchyma Primary · 6 months

The shear wave velocity of the kidneys will be determined using the elastography ultrasound machine. This will enable us to calculate the tissue elasticity using a standard formula. Shear wave velocity is measured in meters per second, at a range of 0-5 m/s with the highest number reporting hard consistency (fibrosis - worse outcome).

Group	Value	95% CI
Shear Wave Elastography Group	0.21	± 0.71

Sponsor's own description

In this proposal, the aim is to examine shear wave elastography (SWE) measurements in diseased native kidneys and correlate them with grades of fibrosis using histological samples. The overall goals of the proposed study are addressed by the following specific aim. Specific aim: To determine whether differences exist in elasticity measurements between native kidneys with and without fibrosis. Hypothesis: Kidneys with higher grades of fibrosis will demonstrate higher measures of tissue elasticity and stiffness compared to kidneys with zero fibrosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Shear wave elastography

Trials testing the same drug.

NCT05328687 — Examination of Muscle Stiffness, Tenderness and Pressure Pain Thresholds During a Cycle of Botulinum Toxin A Treatment i · completed
NCT04456582 — Noninvasive Assessment of Myocardial Stiffness by 2D-SWE Ultrasound Technique (Bidimensional Shear Wave Elastography) in · NA · unknown
NCT03969979 — Elastography in Boys With Epididymo-orchitis · unknown
NCT04267783 — Prediction of Uterine Atony After Vaginal Delivery by Elastography · completed
NCT05419414 — The Use of Shear Wave Elastography, Transvaginal Ultrasound and Pelvic MRI in the Diagnosis of Adenomyosis · NA · completed

Other recruiting trials for Acute Kidney Disease

Currently open trials in the same condition.

NCT07182422 — AST-120 (Kremezin®) for the Renal Protection and Attenuation of Decline in Acute Kidney Disease · Phase 4 · recruiting
NCT05325099 — Demethylating Agent Azacitidine on Prevention of Acute Kidney Injury-chronic Kidney Disease Continuum · Phase 1, PHASE2 · recruiting

Other Albert Einstein Healthcare Network trials

Trials by the same sponsor.

NCT07044323 — Efficacy and Mechanisms of Virtual Reality Treatment of Phantom Leg Pain.Home-Based Treatment · NA · recruiting
NCT06247904 — NIBS Therapy in Subacute Spinal Cord Injury · NA · enrolling by invitation
NCT06028334 — GetUp&Go: A Randomized Controlled Trial of an Intervention to Enhance Physical Activity After TBI · NA · recruiting
NCT04610346 — Assessing an Animal-Assisted Treatment Program for Adults With Aphasia: The Persons With Aphasia Training Dogs Program · NA · completed
NCT05687994 — Speech Entrainment Treatment for People With Aphasia · NA · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02830438 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Albert Einstein Healthcare Network
Last refreshed: 5 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02830438.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing